Association Between Hepatitis C Virus Infection, P53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas

Overview

Journal J Dig Dis Hepatol

Publisher Gavin Publishers

Date 2017 Feb 17

PMID 28203651

Authors

Leona N Council

Chandrakumar Shanmugam

Esther A Suswam

Venkat R Katkoori

Martine J Heslin

Alex Hanna

Nirag C Jhala

Sooryanarayana Varambally

Upender Manne

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the clinical value of p53 codon 72 single nucleotide polymorphisms (SNPs) and variants of adenomatous polyposis coli (APC) in hepatocellular carcinomas (HCCs).

Methods: DNA and RNA from 51 HCCs and their matching, uninvolved liver tissues were analyzed for p53 mutations, and the methylation and expression of APC variants were determined. Proliferation of each HCC was assessed by Ki67 immunohistochemistry. The results were correlated with the demographic and clinicopathologic features and patient survival.

Results: Of 51 HCCs, 12% exhibited missense p53 mutations. SNP analysis of p53 codon 72 demonstrated the highest prevalence of the Arg/Arg (56%) phenotype, followed by Arg/Pro (33%) and Pro/Pro (11%). Four of five cases with the Pro/Pro phenotype were African Americans (AAs). All five cases with the Pro/Pro phenotype had hepatitis C virus (HCV) infections, a high Ki67 index, and lower median survival (15.5 months) compared to those with Arg/Arg or Arg/Pro phenotypes (32 months). The overall frequency of APC methylation was 31%, which was found predominantly in Caucasians. There was lower mRNA expression of APC variants-2 and -3 in both HCCs and corresponding adjacent, uninvolved liver tissues as compared to APC variant-1. The expression of APC variant-3, but not variants-1 and -2, was lower in HCCs relative to uninvolved tissues. Expression of all APC variants was lower in HCCs with APC methylation relative to HCCs without APC methylation, and low expression of APC variant-2 was associated with the Pro/Pro phenotype.

Conclusions: These findings suggest that, for AA patients with HCCs, the p53 Pro/Pro phenotype and low expression of APC variant-2 are associated with aggressive tumor behavior, HCV infection, and poor clinical outcome.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C . Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol. 1998; 72(5):3691-7. PMC: 109590. DOI: 10.1128/JVI.72.5.3691-3697.1998. View

van Engeland M, Weijenberg M, Roemen G, Brink M, de Bruine A, Goldbohm R . Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003; 63(12):3133-7. View

Tan P, Bay B, Yip G, Selvarajan S, Tan P, Wu J . Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2004; 18(3):374-81. DOI: 10.1038/modpathol.3800254. View

Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K . A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993; 18(1):47-53. View

Chen S, Morgan T . The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2):47-52. PMC: 1415841. DOI: 10.7150/ijms.3.47. View

Yu M, Yuan J . Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S72-8. DOI: 10.1016/j.gastro.2004.09.018. View

Hsu H, Peng S, Lai P, Chu J, Lee P . Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 138 patients with unifocal hcc. Int J Oncol. 2011; 4(6):1341-7. DOI: 10.3892/ijo.4.6.1341. View

Altekruse S, Henley S, Cucinelli J, McGlynn K . Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542-53. PMC: 4148914. DOI: 10.1038/ajg.2014.11. View

10.

Pontisso P, Belluco C, Bertorelle R, De Moliner L, Chieco-Bianchi L, Nitti D . Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients. Cancer. 1998; 83(8):1489-94. View

11.

Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle H . Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer. 2003; 106(3):334-41. DOI: 10.1002/ijc.11254. View

12.

Pim D, Banks L . p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2003; 108(2):196-9. DOI: 10.1002/ijc.11548. View

13.

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

14.

Ray R, Steele R, Meyer K, Ray R . Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem. 1997; 272(17):10983-6. DOI: 10.1074/jbc.272.17.10983. View

15.

Lee S, Rho H . Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene. 2000; 19(3):468-71. DOI: 10.1038/sj.onc.1203312. View

16.

Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M . Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer. 2001; 85(1):69-73. PMC: 2363914. DOI: 10.1054/bjoc.2001.1853. View

17.

Katkoori V, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H . Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res. 2009; 15(7):2406-16. PMC: 3635077. DOI: 10.1158/1078-0432.CCR-08-1719. View

18.

Csepregi A, Rocken C, Hoffmann J, Gu P, Saliger S, Muller O . APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2007; 134(5):579-89. PMC: 2757596. DOI: 10.1007/s00432-007-0321-y. View

19.

Hu S, Zhao L, Yang J, Hu M . The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biol. 2013; 35(4):3647-56. DOI: 10.1007/s13277-013-1483-7. View

20.

Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado M . Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000; 60(16):4366-71. View